Please use this identifier to cite or link to this item: http://hdl.handle.net/10739/993
Title: Patent injunction and the public interest in India
Authors: Bharadwaj, Ashish
Keywords: Patent
Public Interest
Pharmaceutical
Injunction
Issue Date: 23-Oct-2017
Publisher: Sweet and Maxwell, London
Citation: European Intellectual Property Review, Vol.40, No.1 (2018)P 54-57
Abstract: The Delhi High Court, in a recent ruling, weighs public interest with injunction in an infringement suit pertaining to a drug patent on new grounds. The decision is functionally a compulsory licensing arrangement, although it is characterized as voluntary licensing. Moreover, the decision sets a dramatic expansion in the scope of patents that fall under the public interest exception to the grant of the patent under the Indian patent law. The decision in 'Bayer' significantly deviates from existing precedence of the Delhi High Court by considering economic interests as sufficient public interest to warrant a refusal to grant an injunction for a patent infringement. It also establishes a kind of de facto compulsory licence by failing to grant an injunction for a company producing a product intended solely for export and not for the domestic market in India. The decision is likely to generate future litigation in India to clarify the scope of the economic basis of the public interest, and it could also lead to international repercussions as patentees attempt to clarify the extent of the public interest exception under TRIPS.
URI: http://www.sweetandmaxwell.co.uk/Catalogue/ProductDetails.aspx?recordid=460
http://hdl.handle.net/10739/993
Appears in Collections:JGU Research Publications

Files in This Item:
File Description SizeFormat 
2018_40_EIPR_Issue_1BHARADWAJ_jgu.pdf277.29 kBAdobe PDFView/Open    Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.